Unicorn Labs

What Unicorn Labs does

Unicorn Labs is a Netherlands-based, pre-revenue-to-early-revenue health-AI company founded in January 2024, operating its core product under the sub-brand Noetika. The platform combines real-time voice analysis with NLP to detect early indicators of cognitive decline and pairs this with a Digital Twin Engine that ingests ADAS-Cog and imaging data to deliver an 84-month disease progression forecast and medication outcome simulation for treating physicians. The product is delivered through a dual-track model: a physician/clinic B2B SaaS (Clinic Starter at $349/month, Advanced at $899/month, custom Enterprise) and a consumer subscription app priced at €22.99/month, €34.99/quarter, or €69.99/year, targeting families and caregivers of individuals with cognitive impairment.

The company is organized around four named executives (CEO Theo Palios, Chief AI Officer Spyretta Leivaditi, External Relations and Operations lead Lan Tran, and Full Stack Developer Pranav Rai), with a hiring footprint of approximately 36 open roles to support a planned full product release in January 2026. As of September 2025, Unicorn Labs has signed three healthcare-provider contracts, validating the B2B channel, and has additionally validated its models on more than 1,000 Alpha users. The company has been awarded the Rabobank Innovation Loan (April 2025), graduated from Startupbootcamp (November 2024) and the Google for Startups Accelerator AI First program (October 2025), and is currently raising a Seed round.

Geographic footprint anchors in Amsterdam with active APAC expansion via Singapore and Vietnam (including partnership exploration with VinUniversity). The combined TAM and SAM are cited at $1.6T and $6.2B respectively, grounded in the 75% undiagnosed rate among dementia patients globally. The platform has multiple AI modalities (audio, text/NLP, structured EHR data) and integrates with existing clinical systems, though there are no public regulatory clearances or third-party clinical validations disclosed, which remains a material gating factor for enterprise healthcare adoption.

Name

Unicorn Labs

Legal name

Unicorn Labs

Website

https://unicornlabs.nl

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Unicorn Labs builds Noetika, an AI-powered voice analysis platform that detects early signs of Alzheimer's and simulates disease progression for physicians, serving clinics, healthcare networks, families, and caregivers via B2B SaaS and consumer subscriptions.

Ownership category

akta.pro rank

Product category

AI-Powered Cognitive Health Diagnostics

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

• Voice-based diagnostics
• Cognitive health monitoring
• AI healthcare software
• Alzheimer's detection platform
• Clinical decision support

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Subscription Software (B2C): Annual subscription model at €69.99/year for consumer users, with monthly (€22.99) and quarterly (€34.99) options. Auto-renews and provides voice-based cognitive assessments and health reports.
2. Clinic Software Tiers: B2B SaaS tiers for healthcare providers: Clinic Starter at $349/month (50 patients, audio analysis, basic forecasting), Advanced at $899/month (200 patients, digital twin simulation, medication management), Enterprise custom pricing with unlimited use and priority support.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Unicorn Labs sells Noetika, an AI-powered voice analysis platform for early detection of Alzheimer's and cognitive decline. The product analyzes speech patterns, tone, hesitation, and cognitive responses using NLP and machine learning. It is offered in two distinct lines: a consumer-facing mobile app for families and caregivers (subscription-based) and a B2B clinical SaaS for healthcare providers featuring a Digital Twin Engine for 84-month disease progression forecasting and medication outcome simulation.

Product overview

Unicorn Labs offers Noetika, an AI-powered voice analysis platform for early Alzheimer's detection. The core product combines real-time voice analysis, NLP processing, and predictive analytics to identify cognitive decline indicators. The platform includes a patient-facing mobile app with features for voice assessments, health reports, and caregiver access, along with a physician dashboard for clinical management. Pricing includes consumer subscription tiers (monthly at €22.99, trimester at €34.99, yearly at €69.99) and clinical tiers (Clinic Starter at $349/mo, Advanced at $899/mo, and Enterprise with custom pricing). The platform also incorporates a Digital Twin Engine for medication simulation and side-effect prediction.

Differentiator

Problem solved

Functional benefit

Brands

• Noetika: AI-powered voice analysis system for early Alzheimer's detection and cognitive health monitoring.

Products and services

• Noetika Consumer App AI-powered voice analysis mobile application for individuals and families that analyzes speech patterns, tone, cognitive responses, and language use during natural voice interactions to detect early signs of Alzheimer's and cognitive decline. Designed for individuals of all ages, including scheduled assessments, personalized health reports, and secure sharing with caregivers and healthcare providers.
• Noetika Clinic Software (Clinical SaaS) B2B clinical SaaS platform for healthcare providers featuring audio analysis, digital twin simulation, medication management, and a physician dashboard. Includes intelligent transcription of patient-doctor conversations, integration with EHR data, medication lists, and historical notes, plus a Disease Progression Timeline visualization for tracking patient status across stages.

Quantifiable outcome

• 94% confidence in AI predictions
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Early Client PartnerscoreStrategic or Co-development Partner · 1 September 2025Signed first client contract in September 2025, quickly followed by two additional contracts, marking transition to revenue-generating company. These healthcare provider partnerships validate commercial traction.
• VinUniversityminorStrategic or Co-development Partner · 1 August 2025Explored partnership during Singaporean delegation visit to Vietnam (Aug 2025) to tap into the APAC market and build relationships with key regional partners.
• Google for Startups Accelerator (GFSA)coreStrategic or Co-development Partner · 1 June 2025Selected for Google for Startups Accelerator AI First program (Jun 2025). Graduated from program in October 2025 at Google Headquarters in Singapore, officially launching Seed fundraising round during this time.
• StartupbootcampcoreStrategic or Co-development Partner · 1 August 2024Selected for prestigious Startupbootcamp accelerator program (Aug 2024), validating the company's potential early on. Graduated in November 2024 with pitch to 300+ investors and industry leaders.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Winterlight Labs: Direct competitor building speech-based digital biomarkers for cognitive impairment and Alzheimer's detection. Named by Unicorn Labs as a key competitor lacking the digital twin/forecasting capability, making it the closest head-to-head in the same product category.
• Altoida: Direct competitor using digital biomarkers (including voice and motor/AR-based assessments) for early detection of neurological conditions including Alzheimer's. Explicitly named by Unicorn Labs; both target similar clinician and pharma customers.
• Cogstate: Digital cognitive assessment platform used by clinicians, pharma, and researchers; offers computerized tests for cognitive function across Alzheimer's, MS, and oncology trials. Comparable as a workflow-embedded cognitive testing vendor to healthcare and pharma customers.
• Cambridge Cognition: Provider of digital cognitive assessments and voice-based cognitive biomarker tools for clinical trials and healthcare. Competes in the same voice-and-digital-biomarker category and overlaps with Winterlight.
• Linus Health: Digital cognitive health platform combining tablet-based assessments, voice analysis, and AI for early detection of dementia and Alzheimer's; serves clinicians, payers, and researchers. Closely comparable product surface and customer set.
• BrainCheck: Digital cognitive assessment platform delivering fast, clinician-administered cognitive tests with EHR integration; serves primary care and specialty practices. Comparable B2B SaaS motion into clinics for cognitive screening.

Emerging players

• Cumulus Neuroscience: Neuroscience platform combining digital and EEG biomarkers for CNS trial measurement, including Alzheimer's. Adjacent category (digital biomarkers for neurology) with overlap on the pharma-trial use case.
• Neuronostics: UK-based startup developing AI-driven EEG-based digital biomarkers for neurological conditions including dementia. Early-stage peer with overlapping biomarker-plus-AI approach to early detection.

Broad incumbents

• Roche (F. Hoffmann-La Roche): Global pharma incumbent heavily invested in Alzheimer's diagnostics, treatments (e.g., gantenerumab programs), and digital biomarker partnerships. Serves as both a potential partner and a powerful incumbent competitor for payer/pharma adoption.
• Biogen: Alzheimer's-focused biopharma with lecanemab and ongoing diagnostic initiatives. Relevant as a potential enterprise customer for early-detection tooling and as a competitor shaping the standards digital diagnostics must meet.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/101107012
• Xx.com/unicornlabsbv

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unicorn Labs